DLL3 on circulating tumor cells predicts tarlatamab success in lung cancer

By News Medical January 14, 2026 #Cancer, #Cells, #Circulating, #DLL3, #Health, #Lung, #Medical, #medicine, #Predicts, #success, #Tarlatamab, #tumor

A team led by investigators at the Mass General Brigham Cancer Institute has discovered that a particular marker on tumor cells circulating in the blood indicates whether a patient with lung cancer will experience a lasting response to a newly approved immunotherapy called tarlatamab.